IGC Pharma has announced the expansion of its Phase 2 CALMA clinical trial to include a prominent research center in Colombia. This addition aims to increase the genetic diversity of trial participants and enhance the robustness of the study’s findings.
The new site, recognized globally for its expertise in genetics and neuroscience, will contribute to the ongoing efforts to advance the development of treatments for Alzheimer’s disease. The company remains on track to present key data from the trial in 2026.
**Why this matters**
Expanding the trial to Colombia’s top Alzheimer’s research center allows for a more diverse participant pool, which can improve the generalizability of the results. This step also strengthens the overall study design, potentially accelerating the path toward effective therapies for Alzheimer’s disease.
Source: NewsData